Jennifer Arnold, MD

Jennifer Arnold, MD

Assistant Professor, Neurology
Neurology

    About me

    Gender

    Female

    Education & training

    Positions
    Neurologist
    Medical School
    MD, University of Illinois
    Doctorate Degree
    Ph.D. Molecular and Integrative Physiology, University of Illinois at Urbana-Champaign
    Undergraduate Degree
    BS Biology, Southeast Missouri State University
    Residency
    Neurology, University of Michigan
    Fellowship
    Neurodegenerative Diseases, University of Michigan

    Clinical trials

    Trial
    Neurology

    Roche: An open-label, multicenter, rollover study to evaluate the safety, tolerability, and efficacy of long-term gantenerumab administration in participants with Alzheimer's disease

    Active not recruiting

    POST GRAD: The purpose of this study is to compare the effects, good or bad, of long term gantenerumab on subjects with prodromal or mild Alzheimer's disease. 

    Contact: Sara Boarman 217-545-6829
    Trial
    Neurology

    Lilly: Assessment of Safety, Tolerability, and Efficacy of Donanemab in Early Symptomatic Alzheimer's Disease

    Active not recruiting

    I5T-MC-AACI: Alzheimer’s is a disease that attacks the brain, causing problems with memory, thinking, and behavior.  Symptoms usually develop slowly and get worse over time, eventually making daily tasks impossible. Although we don’t know the exact cause, researchers found out that the two proteins called tau and amyloid are building up in brains of people with Alzheimer’s disease even before they have any symptoms.

    Contact: Barbara Lokaitis 217-545-9737
    Trial
    Neurology

    Lilly: Assessment of Safety, Tolerability, and Efficacy of Donanemab in Early Symptomatic Alzheimer's Disease

    Active not recruiting

    I5T-MC-AACI: Alzheimer’s is a disease that attacks the brain, causing problems with memory, thinking, and behavior.  Symptoms usually develop slowly and get worse over time, eventually making daily tasks impossible. Although we don’t know the exact cause, researchers found out that the two proteins called tau and amyloid are building up in brains of people with Alzheimer’s disease even before they have any symptoms.

    Contact: Barbara Lokaitis 217-545-9737
    Trial
    Neurology

    Athira: A Randomized, Placebo-Controlled, Double-Blind, Dose-Ranging Study to Evaluate Safety and Efficacy of ATH-1017 Treatment in Alzheimer’s Dementia Patients

    Active recruiting

    ATH-1017-AD-201: The purpose of this study is to compare the effects, good or bad, of ATH-1017 on patients with mild to moderate Alzheimer's Disease.

    Contact: Sara Boarman 217-545-6829
    Trial
    Neurology

    Athira: A Randomized, Placebo-Controlled, Double-Blind, Dose-Ranging Study to Evaluate Safety and Efficacy of ATH-1017 Treatment in Alzheimer’s Dementia Patients

    Active recruiting

    ATH-1017-AD-201: The purpose of this study is to compare the effects, good or bad, of ATH-1017 on patients with mild to moderate Alzheimer's Disease.

    Contact: Sara Boarman 217-545-6829

    Related articles

    Arnold

    Meet Jennifer Arnold, MD

    What brought you to SIU Medicine? I was born in Springfield and spent all of my childhood here, leaving only to go to college, then medical and graduate school. I always knew I wanted to return home